Loading
A phase 1/2 trial of Disitamab vedotin in advanced solid tumours, run by Pfizer, active and no longer recruiting.
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer is a phase 1/2 interventional study registered as NCT06966453 by Pfizer, with 74 participants enrolled, started 2025-06-30 and due to reach its primary completion in 2027-10-25. Interventions recorded: Disitamab vedotin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Disitamab vedotin, Pfizer (incl. Seagen), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Disitamab vedotin, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Disitamab vedotin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Disitamab vedotin, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Pfizer (incl. Seagen), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/